Expert Opinion on Emerging Drugs最新文献_第7页

Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma. 新兴的单克隆抗体治疗转移性尿路上皮癌。

IF 3.4 3区医学

Expert Opinion on Emerging Drugs Pub Date : 2023-03-01 DOI: 10.1080/14728214.2023.2186398

Rohit K Jain, Avani M Singh, Xuefeng Wang, José A Guevara-Patiño, Guru Sonpavde

{"title":"Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma.","authors":"Rohit K Jain, Avani M Singh, Xuefeng Wang, José A Guevara-Patiño, Guru Sonpavde","doi":"10.1080/14728214.2023.2186398","DOIUrl":"https://doi.org/10.1080/14728214.2023.2186398","url":null,"abstract":"Introduction: The treatment landscape for advanced-stage, unresectable or metastatic urothelial carcinoma (mUC) has shifted dramatically over a short period of time, with new therapeutic agents available for clinical use. However, despite these recent advances in the field, mUC continues to be a disease with significant morbidity and mortality and remains generally incurable. While platinum-based therapy remains the backbone of therapy, many patients are ineligible for chemotherapy or have failed initial chemotherapy treatment. In post-platinum treated patients, immunotherapy and antibody drug conjugates have provided incremental advances, but agents with better therapeutic index guided by precision medicine are needed.Areas covered: This article covers the available monoclonal antibody therapies in mUC excluding immunotherapy and antibody drug conjugates. Included are a review of data utilizing monoclonal antibodies targeting VEG-F, HER-2, FGFR, and KIR-2 in the setting of mUC. A literature search from 6/2022- 9/2022 was performed utilizing PubMed with key terms including urothelial carcinoma, monoclonal antibody, VEG-F, HER-2, FGFR.Expert opinion: Often used in combination with immunotherapy or other therapeutic agents, monoclonal antibody therapies have exhibited efficacy in mUC in early trials. Upcoming clinical trials will further explore their full clinical utility in treating mUC patients.","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":"28 1","pages":"17-26"},"PeriodicalIF":3.4,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9661305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A review of emerging factor XI inhibitors.

IF 3.4 3区医学

Expert Opinion on Emerging Drugs Pub Date : 2023-03-01 DOI: 10.1080/14728214.2023.2192923

Sandra Elsheikh, Nicola Tidbury, Gregory Y H Lip

{"title":"A review of emerging factor XI inhibitors.","authors":"Sandra Elsheikh, Nicola Tidbury, Gregory Y H Lip","doi":"10.1080/14728214.2023.2192923","DOIUrl":"https://doi.org/10.1080/14728214.2023.2192923","url":null,"abstract":"Introduction: Whilst the introduction of direct oral anticoagulants (DOACs) has improved the prevention of thromboembolic events, there is still a need for safer anticoagulants. This is particularly so, for specific populations of patients, such as those with an increased bleeding risk or those with severely reduced kidney function. People with Factor XI (FXI) deficiency are at reduced risk of thromboembolic events, without an increased risk of spontaneous bleeding. FXI inhibition, therefore, presents the ideal target for novel anticoagulants.Areas covered: In this review, we provide an overview of the currently available anticoagulants and the emerging FXIa inhibitors in clinical trials. The need for availability of novel anticoagulants and the potential issues that will hinder the development and marketing of factor XIa inhibitors is also discussed.Expert opinion: Evidence suggests that FXI inhibition presents a promising drug target for novel anticoagulation therapies. The FXIa inhibitors in development have advantages over DOACs with lower renal clearance and long half-lives. Overall, FXI inhibition presents a promising target, it is likely that the clinical use of FXIa inhibitors is on the horizon.","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":"28 1","pages":"43-53"},"PeriodicalIF":3.4,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9646897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Emerging antiviral therapies and drugs for the treatment of influenza. 新兴的抗病毒疗法和治疗流感的药物。

IF 3.4 3区医学

Expert Opinion on Emerging Drugs Pub Date : 2022-12-01 DOI: 10.1080/14728214.2022.2149734

Jinshen Wang, Yihang Sun, Shuwen Liu

{"title":"Emerging antiviral therapies and drugs for the treatment of influenza.","authors":"Jinshen Wang, Yihang Sun, Shuwen Liu","doi":"10.1080/14728214.2022.2149734","DOIUrl":"https://doi.org/10.1080/14728214.2022.2149734","url":null,"abstract":"Introduction: Both vaccines and antiviral drugs represent the mainstay for preventing and treating influenza. However, approved M2 ion channel inhibitors, neuraminidase inhibitors, polymerase inhibitors, and various vaccines cannot meet therapeutic needs because of viral resistance. Thus, the discovery of new targets for the virus or host and the development of more effective inhibitors are essential to protect humans from the influenza virus.Areas covered: This review summarizes the latest progress in vaccines and antiviral drug research to prevent and treat influenza, providing the foothold for developing novel antiviral inhibitors.Expert opinion: Vaccines embody the most effective approach to preventing influenza virus infection, and recombinant protein vaccines show promising prospects in developing next-generation vaccines. Compounds targeting the viral components of RNA polymerase, hemagglutinin and nucleoprotein, and the modification of trusted neuraminidase inhibitors are future research directions for anti-influenza virus drugs. In addition, some host factors affect the replication of virus in vivo, which can be used to develop antiviral drugs.","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":"27 4","pages":"389-403"},"PeriodicalIF":3.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10493562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Emerging drugs for the treatment of alopecia areata. 治疗斑秃的新药物。

IF 3.4 3区医学

Expert Opinion on Emerging Drugs Pub Date : 2022-12-01 DOI: 10.1080/14728214.2022.2149735

Hassiel Aurelio Ramírez-Marín, Antonella Tosti

{"title":"Emerging drugs for the treatment of alopecia areata.","authors":"Hassiel Aurelio Ramírez-Marín, Antonella Tosti","doi":"10.1080/14728214.2022.2149735","DOIUrl":"https://doi.org/10.1080/14728214.2022.2149735","url":null,"abstract":"Introduction: Alopecia Areata (AA) is the second most common non-scarring hair loss disorder, with a prevalence of 1 in 1000 and a lifetime incidence of 2% worldwide. Data from a recent American study shows that from 68,121 patients with the diagnosis of AA, 37,995 (55.8%) were prescribed treatment for AA within a year of diagnosis, however there are still no therapies able to induce permanent remission, or treatments that guarantee hair regrowth/remissions in 100% of cases, especially in longstanding/severe AA. Recently, oral baricitinib has been approved for AA, being the first drug approved for this specific indication.Areas covered: The current review will provide a summary of current pharmacological approaches and novel therapeutics in development.Expert opinion: New and very effective drugs have become available for the treatment of severe AA, and many others are expected soon. However, even new, effective treatments are not effective in all patients and recurrence rates after treatment interruption are high. AA is a systemic disease with important impact on quality of life and should not be considered just as an aesthetic problem. Treatment of the disease should take in account and possibly also address treatment of comorbidities.","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":"27 4","pages":"379-387"},"PeriodicalIF":3.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10842746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Existing and emerging therapies for the treatment of invasive candidiasis and candidemia. 侵袭性念珠菌病和念珠菌病的现有和新兴治疗方法。

IF 3.4 3区医学

Expert Opinion on Emerging Drugs Pub Date : 2022-12-01 DOI: 10.1080/14728214.2022.2142207

David De Bels, Evelyne Maillart, Françoise Van Bambeke, Sebastien Redant, Patrick M Honoré

{"title":"Existing and emerging therapies for the treatment of invasive candidiasis and candidemia.","authors":"David De Bels, Evelyne Maillart, Françoise Van Bambeke, Sebastien Redant, Patrick M Honoré","doi":"10.1080/14728214.2022.2142207","DOIUrl":"https://doi.org/10.1080/14728214.2022.2142207","url":null,"abstract":"Introduction: Invasive candidiasis or candidemia is a severe infection affecting more than 250,000 people worldwide every year. It is present in up to 16% of ICU patients. The prognosis of these infections is unfavorable, with global death estimated around 50,000 per year, which corresponds to up to 40% depending on patient severity and comorbidities. Therapeutic failure is not rare due to the emergence of multiresistant strains and of new species poorly responsive to current therapies like Candida auris.Areas covered: We first review the positioning of antifungal drugs used to treat candidiasis, namely polyenes, azoles, echinocandins and pyrimidine analogues. We then discuss the progresses brought by new formulations, new derivatives within these classes, compounds acting on new targets or repurposed drugs in terms of pharmacokinetic profile, spectrum of activity, potency, safety or risk of drug-drug interactions.Expert opinion: While new formulations (amphotericin B cochleate) improve oral bioavailability of the corresponding drugs, new azoles or echinocandins offer higher potency including against strains resistant to former generations of drugs. Repurposed drugs show synergism with current therapies in vitro. Results from ongoing and future clinical trials will be decisive to establish the interest for these drugs in our arsenal.","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":"27 4","pages":"405-416"},"PeriodicalIF":3.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10483989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa. 针对 RPGR 相关 X 连锁色素性视网膜炎的新兴基因治疗产品。

IF 3.4 3区医学

Expert Opinion on Emerging Drugs Pub Date : 2022-12-01 DOI: 10.1080/14728214.2022.2152003

Cristina Martinez-Fernandez de la Camara, Jasmina Cehajic-Kapetanovic, Robert E MacLaren

{"title":"Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa.","authors":"Cristina Martinez-Fernandez de la Camara, Jasmina Cehajic-Kapetanovic, Robert E MacLaren","doi":"10.1080/14728214.2022.2152003","DOIUrl":"10.1080/14728214.2022.2152003","url":null,"abstract":"Introduction: Mutations in the RPGR gene are responsible for one of the most prevalent and severe types of retinitis pigmentosa. Gene therapy has shown great promise to treat inherited retinal diseases, and currently, four RPGR gene therapy vectors are being evaluated in clinical trials.Areas covered: This manuscript reviews the gene therapy products that are in development for X-linked retinitis pigmentosa caused by mutations in RPGR, and the challenges that scientists and clinicians have faced.Expert opinion: The development of a gene therapy product for RPGR-associated retinal degeneration has been a great challenge due to the incomplete understanding of the underlying genetics and mechanism of action of RPGR, and on the other hand, due to the instability of the RPGR gene. Three of the four gene therapy vectors currently in clinical trials include a codon-optimized version of the human RPGR sequence, and the other vector contains a shortened version of the human RPGR. To date, the only Phase I/II results published in a peer-reviewed journal demonstrate a good safety profile and an improvement in the visual field using a codon optimized version of RPGRORF15.","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":"27 4","pages":"431-443"},"PeriodicalIF":3.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10502303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging drugs for the treatment of inflammatory bowel disease. 治疗炎症性肠病的新药物。

IF 3.4 3区医学

Expert Opinion on Emerging Drugs Pub Date : 2022-12-01 DOI: 10.1080/14728214.2022.2147507

Uni Wong, Raymond K Cross

{"title":"Emerging drugs for the treatment of inflammatory bowel disease.","authors":"Uni Wong, Raymond K Cross","doi":"10.1080/14728214.2022.2147507","DOIUrl":"https://doi.org/10.1080/14728214.2022.2147507","url":null,"abstract":"Introduction: Anti-tumor necrosis factor (TNF)-α have been the mainstay therapy for Crohn's (CD) and ulcerative colitis (UC) for decades. With growing need for highly effective therapy, various therapeutic targets have been introduced including anti-integrins, anti-interleukin (IL) 12/23, selective anti-IL23, Janus Kinase (JAK) inhibitors, sphingosine-1-phosphate (S1P) receptor modulators, and mRNA-124 splicing agent.Areas covered: The current state of available IBD therapies and those in development are reviewed, with recommendations made on positioning in clinical practice.Expert opinion: Selecting and sequencing IBD therapies remains a clinical challenge. Disease phenotype, severity of symptoms, patient comorbidities, and prior drug exposure should be considered when considering therapy options. Anti-TNF remains a time-tested option that is effective in both UC and CD. The perception that newer biologics have slower onset of action is probably overestimated and providers should reconsider need for concurrent corticosteroid. JAK-inhibitors provide rapid symptom improvement in patients with moderate-severe UC. Due to safety concerns, it is recommended as a second-line therapy for UC. The goal for IBD treatment should be personalized, have rapid onset of action, induce durable clinical and endoscopic remission, and have excellent safety.","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":"27 4","pages":"369-377"},"PeriodicalIF":3.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10842737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Response: 'letter to the editor: emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa'. 回复：致编辑的信：RPGR 相关 X 连锁色素性视网膜炎的新兴基因治疗产品"。

IF 3.4 3区医学

Expert Opinion on Emerging Drugs Pub Date : 2022-12-01 DOI: 10.1080/14728214.2022.2152212

Cristina Martinez-Fernandez de la Camara, Jasmina Cehajic-Kapetanovic, Robert E MacLaren

引用次数: 0

Letter to the editor: 'Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa'. 致编辑的信:“rpcr相关x连锁视网膜色素变性的新兴基因治疗产品”。

IF 3.4 3区医学

Expert Opinion on Emerging Drugs Pub Date : 2022-12-01 DOI: 10.1080/14728214.2022.2152202

Anastasios Georgiadis, Alexander J Smith, Michel Michaelides, Stuart Naylor, Alexandria Forbes

引用次数: 0

Emerging drugs for the treatment of diabetic nephropathy. 治疗糖尿病肾病的新药物。

IF 3.4 3区医学

Expert Opinion on Emerging Drugs Pub Date : 2022-12-01 DOI: 10.1080/14728214.2022.2155632

Yoon Kook Kim, Xinyuan Ning, Kashif M Munir, Stephen N Davis

{"title":"Emerging drugs for the treatment of diabetic nephropathy.","authors":"Yoon Kook Kim, Xinyuan Ning, Kashif M Munir, Stephen N Davis","doi":"10.1080/14728214.2022.2155632","DOIUrl":"https://doi.org/10.1080/14728214.2022.2155632","url":null,"abstract":"Introduction: Diabetic nephropathy remains a significant economic and social burden on both the individual patient and health-care systems as the prevalence of diabetes increases in the general population. The complex pathophysiology of diabetic kidney disease poses a challenge in the development of effective medical treatments for the disease. However, the multiple facets of diabetic nephropathy also offer a variety of potential strategies to manage this condition.Areas covered: We retrieved PubMed, Cochrane Library, Scopus, Google Scholar, and ClinicalTrials.gov records to identify studies and articles focused on new pharmacologic advances to treat diabetic nephropathy.Expert opinion: RAAS blockers have remained the mainstay of therapy for DM nephropathy for many years, with only recent advancements with SGLT2 inhibitors and nonsteroidal MRAs. Better understanding of the long-term renal effects of ambient hyperglycemia, ranging from hemodynamic changes to increased production of oxidative and pro-inflammatory substances, has evolved our approach to the treatment of diabetic nephropathy. With continuing research for new therapeutics as well as combination therapy, the medical community may be able to better ease the burden of diabetic kidney disease.","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":"27 4","pages":"417-430"},"PeriodicalIF":3.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10491179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0